However, the NCCN guidelines propose annually screening for PHEO (MEN 2A and MEN 2B) and PHTH (MEN 2A), while for carriers of RET PVs in codons 768, 790, 804, or 891, less frequent screening may be appropriate [9]. Here, RET is linked to multiple endocrine neoplasia.